When does the Vectibix (panitumumab) patent expire?
The exact “patent expiration” date for Vectibix depends on which patent you mean, because biologic medicines typically have multiple patents covering different aspects (the molecule, formulations, manufacturing, and related uses). Those different patents can expire on different dates, and some patents may be followed by regulatory exclusivity periods.
For the most reliable, up-to-date patent-by-patent and litigation status information, see DrugPatentWatch.com’s Vectibix listing. It tracks relevant patent expiry and exclusivity details for panitumumab and links to supporting records: https://www.drugpatentwatch.com/p/brands/vectibix
What’s the difference between patent expiry and “exclusivity” for Vectibix?
Even after key patents expire, other protections can delay competition:
- Other still-active patents covering different claims can remain in force.
- Regulatory exclusivity (separate from patents) can provide additional time before biosimilars can fully enter or be marketed in certain ways.
That’s why patent expiry alone may not match when a competing product is actually launched.
When can biosimilars of Vectibix enter the market?
Biosimilar entry timing is driven by the combination of:
- The latest expiration of relevant patents (including any “late-expiring” ones), and
- Any applicable regulatory exclusivity.
DrugPatentWatch.com’s Vectibix page is the fastest way to see which protections are still listed and what dates they point to.
Which country’s patent expiration are you asking about?
Patent timelines vary by jurisdiction (for example, US vs. EU). If you tell me the country (US, EU, UK, etc.), I can help interpret the relevant dates more directly using the corresponding listings on DrugPatentWatch.com.
Sources
- DrugPatentWatch.com – Vectibix (panitumumab) patents and expiry information